Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySierra Health and Life FcRn blocker Coverage Updat…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0111O

    FcRn blocker therapies for generalized myasthenia gravis

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0111O alerts

    Get alerted when Policy 2026D0111O changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria and authorization requirements for medical benefit use of FcRn blockers (Imaavy, Rystiggo, Vyvgart, Vyvgart Hytrulo) to treat generalized myasthenia gravis (gMG) in specified antibody-positive patients; affects prescribers and prior authorization reviewers.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    Payersierra health and life
    PolicyFcRn blocker therapies for generalized myasthenia gravis
    Policy CodePolicy 2026D0111O
    Change TypeMaterial revisions to drug list, concomitant therapy exclusions, and Vyvgart criteria
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical records showing diagnosis, antibody status, MGFA class II–IV, baseline MG-ADL ≥ 5, and required prior therapy failures.
    SourceLink
    POLICY UPDATE CHANGES

    Imaavy (nipocalimab-aahu) was added for intravenous (IV) administration and listed among applicable drug products administered by a healthcare professional.

    Revised list of concomitant drug products patients must not be receiving in combination with Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo to include CD19-directed cytolytic antibodies and to update FcRn blocker examples.

    Coverage criteria for Vyvgart and Vyvgart Hytrulo were revised; removed criterion requiring a minimum 50-day interval between treatment cycles.

    4drug products referenced
    ≥5MG-ADL threshold
    II–IVMGFA class required
    ≤12 monthsauth duration
    2‑point MG-ADLcontinuation response

    Coverage Criteria for FcRn Blockers

    inv-01: Imaavy Initial Therapy

    Imaavy (nipocalimab-aahu) is medically necessary when ALL of the following are met:

    Imaavy Initial Therapy: Submission of medical records confirming: patient has not previously failed a course of Imaavy; diagnosis of generalized myasthenia gravis (gMG); positive serologic test for anti-AChR or anti-MuSK antibodies; MGFA Clinical Classification II, III, or IV at initiation; MG-ADL total score >= 5 at initiation; dosing per US FDA label for gMG; prescribed by or in consultation with a neurologist; initial authorization for no more than 12 months.MG-ADL >= 5
    Prior therapy requirements by serostatus (anti-AChR): If anti-AChR antibody positive: either history of failure of at least two immunosuppressive agents over the course of at least 12 months OR history of failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.see text

    For Medicare reviews, refer to CMS section.

    Prior therapy requirements by serostatus (anti-MuSK): If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over the course of at least 12 months.see text
    Concomitant therapy exclusions: Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody (e.g., inebilizumab), a complement inhibitor (e.g., eculizumab, ravulizumab, zilucoplan), an FcRn blocker (e.g., Rystiggo, Vyvgart, Vyvgart Hytrulo), or an immune globulin (e.g., Hizentra, Privigen, Gammagard).

    inv-02: Imaavy Continuation Therapy

    Imaavy continuation is allowed when ALL of the following are met:

    Imaavy Continuation: Patient has previously been treated with Imaavy; submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement in MG-ADL from pre-treatment baseline; reduction in signs and symptoms of myasthenia gravis; maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (add-on, escalation, or additional rescue therapy is considered treatment failure); patient is not receiving excluded concomitant therapies (CD19-directed cytolytic antibody, complement inhibitor, another FcRn blocker, or immune globulin); dosing per US FDA label; prescribed by or in consultation with a neurologist; reauthorization for no more than 12 months.>=2 point MG-ADL improvement

    Documentation of MG-ADL change and IST status required in records.

    inv-03: Rystiggo Initial Therapy

    Rystiggo (rozanolixizumab-noli) is medically necessary when ALL of the following are met:

    Rystiggo Initial Therapy: Submission of medical records confirming: patient has not previously failed a course of Rystiggo; diagnosis of generalized myasthenia gravis (gMG); positive serologic test for anti-AChR or anti-MuSK antibodies; MGFA Clinical Classification II, III, or IV at initiation; MG-ADL total score >= 5 at initiation; dosing per US FDA label for gMG; prescribed by or in consultation with a neurologist; initial authorization for no more than 12 months; patient will not receive Rystiggo sooner than 63 days from the start of the previous treatment cycle; and not receiving excluded concomitant therapies.MG-ADL >= 5
    Rystiggo Serology and prior therapy (AChR): If anti-AChR antibody positive: either history of failure of at least two immunosuppressive agents over at least 12 months OR history of failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.see text
    Rystiggo Serology and prior therapy (MuSK):

    inv-04: Rystiggo Continuation Therapy

    Rystiggo continuation is allowed when ALL of the following are met:

    Rystiggo Continuation: Patient has previously been treated with Rystiggo; submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement in MG-ADL from pre-treatment baseline; reduction in signs and symptoms of myasthenia gravis; maintenance, reduction, or discontinuation of baseline IST (add-on, escalation, or additional rescue therapy is considered treatment failure); patient is not receiving excluded concomitant therapies; patient is not being given Rystiggo sooner than 63 days from the start of the previous treatment cycle; dosing per US FDA label; prescribed by or in consultation with a neurologist; reauthorization for no more than 12 months.>=2 point MG-ADL improvement

    inv-05: Vyvgart Initial and Continuation Therapy

    Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo are medically necessary when ALL of the following are met:

    Vyvgart Initial Therapy: Submission of medical records confirming: patient has not previously failed a course of Vyvgart or Vyvgart Hytrulo; diagnosis of generalized myasthenia gravis (gMG); positive serologic test for anti-AChR antibodies; MGFA Clinical Classification II, III, or IV at initiation; MG-ADL total score >= 5 at initiation; history of failure of at least two immunosuppressive agents over at least 12 months OR failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control; dosing per US FDA label for gMG; prescribed by or in consultation with a neurologist; initial authorization for no more than 12 months; not receiving excluded concomitant therapies (CD19-directed cytolytic antibody, complement inhibitor, FcRn blocker, or immune globulin).MG-ADL >= 5

    For Medicare reviews, refer to CMS section.

    Vyvgart Continuation: Patient has previously been treated with Vyvgart or Vyvgart Hytrulo; submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement in MG-ADL from pre-treatment baseline; reduction in signs and symptoms of myasthenia gravis; maintenance, reduction, or discontinuation of baseline IST (add-on, escalation, or additional rescue therapy is considered treatment failure); patient is not receiving excluded concomitant therapies; dosing per US FDA label; prescribed by or in consultation with a neurologist; reauthorization for no more than 12 months.

    inv-06: Vyvgart / Vyvgart Hytrulo initial therapy for refractory gMG

    Covered when ALL of the following are met:

    Prior therapy failures: History of failure of at least two immunosuppressive agents over at least 12 months OR failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.see text

    Medicare reviews refer to CMS section.

    No concomitant excluded agents: Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody, a complement inhibitor, an FcRn blocker, or an immune globulin.
    Dosing and prescriber: Dosed according to US FDA labeled dosing for gMG and prescribed by or in consultation with a neurologist; initial authorization for no more than 12 months.

    inv-07: Vyvgart / Vyvgart Hytrulo continuation for gMG

    Covered when ALL of the following are met:

    Prior treatment: Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
    Objective benefit: Medical records demonstrating at least a 2-point improvement in MG-ADL from pre-treatment baseline and reduction in signs and symptoms of myasthenia gravis, AND maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (no escalation or additional rescue therapy); documentation of sustained benefit required for continuation.MG-ADL Δ ≤ -2

    Continuation requires documentation of sustained benefit; reauthorization ≤ 12 months.

    inv-08: Vyvgart Hytrulo initial therapy for CIDP

    Vyvgart Hytrulo is medically necessary for CIDP when ALL of the following are met:

    Diagnosis requirements: Patient has not failed a previous course of Vyvgart Hytrulo; diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) confirmed by: progressive symptoms for at least 2 months; symptomatic polyradiculoneuropathy affecting more than one limb (progressive or relapsing motor or sensory impairment); and electrodiagnostic findings consistent with EFNS/PNS criteria (motor distal latency prolongation in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolongation or absence of F-waves; partial motor conduction block; abnormal temporal dispersion; distal CMAP duration increase as specified).see text

    Electrodiagnostic specifics provided in policy.

    Prior therapy: Trial and failure (after at least 2 months) of corticosteroids AND trial and failure (after at least 3 months) of an immune globulin (IVIG/SCIG), OR documented intolerance/contraindication to immune globulin with dose escalation to maximally tolerated dose, OR contraindication to all immune globulins.see text

    For Medicare reviews, refer to CMS section.

    inv-09: Vyvgart Hytrulo continuation for CIDP

    Covered when ALL of the following are met:

    Prior treatment: Patient has previously been treated with Vyvgart Hytrulo.
    Objective response: Documentation of positive clinical response to therapy measured by an objective scale (e.g., Rankin, Modified Rankin, Medical Research Council [MRC] scale); patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.

    Dosing per US FDA label and prescribed by/with neurologist; reauthorization for no more than 12 months.

    Dosing and prescriber: Vyvgart Hytrulo dosed according to US FDA labeled dosing for CIDP and prescribed by or in consultation with a neurologist; reauthorization for no more than 12 months.

    inv-10: Imaavy (nipocalimab-aahu) Initial Therapy

    Covered when ALL of the following are met

    Imaavy initial therapy: Patient has diagnosis of generalized myasthenia gravis; submission of medical records confirming no prior Imaavy exposure; positive serologic test for anti-AChR or anti-MuSK antibodies; MGFA Clinical Classification II, III, or IV; MG-ADL total score >= 5; dosing per US FDA label; prescribed by or in consultation with a neurologist; initial authorization for no more than 12 months.MG-ADL >= 5
    Prior therapy requirements by serostatus: If anti-AChR positive: either failure of at least two immunosuppressive agents over >=12 months OR failure of at least one immunosuppressive plus >=4 courses of plasmapheresis/IVIG over >=12 months. If anti-MuSK positive: failure of at least one immunosuppressive agent over >=12 months.see text
    Concomitant therapy exclusions: Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody, a complement inhibitor, an FcRn blocker, or an immune globulin.

    inv-11: Imaavy Continuation Therapy

    Covered when ALL of the following are met

    Continuation of Imaavy: Patient previously treated with Imaavy; medical records show at least a 2-point improvement in MG-ADL from pre-treatment baseline and reduction in signs and symptoms of MG; maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (increase or additional rescue therapy is considered treatment failure); patient not receiving prohibited concomitant therapies; dosing per US FDA label; prescribed by or in consultation with a neurologist; reauthorization for no more than 12 months.>=2 point MG-ADL improvement

    Documentation of MG-ADL and IST changes required.

    inv-12: CIDP (efgartigimod alfa + hyaluronidase) Evidence and Diagnostic Criteria

    Clinical trial and diagnostic context

    CIDP trial evidence: Stage B randomized withdrawal trial enrolled 221 patients with definite or probable CIDP per EFNS/PNS criteria; primary endpoint time to clinical deterioration (1-point aINCAT increase) showed efgartigimod alfa + hyaluronidase-qvfc prolonged time to deterioration (hazard ratio 0.394, p<0.0001).
    CIDP diagnostic criteria: Use the 2021 EAN/PNS revised clinical and electrodiagnostic criteria to define typical CIDP and variants; electrodiagnostic parameters strongly supportive of demyelination are listed (motor distal latency prolongation ≥50% above ULN in two nerves; reduction of motor conduction velocity ≥30% below LLN in two nerves; F-wave prolongation/absence; motor conduction block; temporal dispersion; distal CMAP duration prolongation) and are used to confirm diagnosis for the CIDP pathway.see text

    Electrodiagnostic numeric cutoffs provided in policy.

    Use of FcRn blockers in combination with certain other immunomodulatory agents is explicitly excluded. Specifically, patients must not be receiving these FcRn blocker products in combination with a CD19-directed cytolytic antibody (e.g., Uplizna/inebilizumab), a complement inhibitor (e.g., eculizumab, ravulizumab, zilucoplan), another FcRn blocker (examples include Rystiggo, Vyvgart, Vyvgart Hytrulo, Imaavy), or an immune globulin (e.g., Hizentra, Privigen, Gammagard).

    Rystiggo has an operational timing restriction: doses must not be administered sooner than 63 days from the start of the previous treatment cycle. This interval is reiterated for continuation requests and should be checked during prior authorization and refill reviews to ensure dosing cadence meets the policy requirement.

    In summary, combination use of FcRn blockers with the following classes is disallowed: CD19-directed cytolytic antibodies, complement inhibitors, other FcRn blockers, and immune globulins. The policy lists specific examples for each class (e.g., Uplizna; eculizumab, ravulizumab, zilucoplan; Imaavy, Rystiggo, Vyvgart, Vyvgart Hytrulo; Hizentra, Privigen, Gammagard) and prior authorization reviews should flag any concurrent therapy from these groups as noncompliant with coverage criteria.

    Policy revisions update the combination-exclusion language to explicitly include Imaavy (nipocalimab-aahu) among FcRn blocker examples and to add CD19-directed cytolytic antibodies to the prohibited-concomitant list. These operational changes affect prior authorization checks and should be used when verifying that a patient is not receiving any prohibited agent concurrently with the requested therapy.

    Requests that propose initiating or continuing FcRn blocker therapy without the required prior therapy history, or that document concurrent use of any excluded agents, are not supported by the policy and are subject to denial. Reviewers should cite the absence of documented failures of required immunosuppressive therapies or the presence of a prohibited concomitant agent when issuing an operational denial.

    The policy revisions specifically removed a prior 50-day interval requirement for Vyvgart/Vyvgart Hytrulo cycles and standardized the prohibited-concomitant therapy lists across agents. Operationally, this means reviewers should no longer enforce a 50-day minimum interval for Vyvgart products but must continue to enforce updated combination-exclusion checks that now list CD19-directed cytolytic antibodies and revised FcRn blocker examples.

    Billing and Diagnosis Codes

    Referenced HCPCS/J-codesHCPCS
    J9256Injection, nipocalimab-aahu, 3 mg.
    J9332Injection, efgartigimod alfa-fcab, 2 mg.
    J9333Injection, rozanolixizumab-noli, 1 mg.
    J9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
    Referenced ICD-10 codesICD-10
    G61.81Chronic inflammatory demyelinating polyneuritis.
    G70.00Myasthenia gravis without (acute) exacerbation.
    G70.01Myasthenia gravis with (acute) exacerbation.
    No explicit codes in this document sectionmixed
    No codes listed
    inv-22: MG-ADL score — baseline and continuation thresholds
    Baseline MG-ADL (initiation)MG-ADL total score ≥ 5 at initiation
    Continuation threshold (absolute change)≥ 2 point improvement in MG-ADL from pre-treatment baseline
    Sustained improvement requirementImprovement must be documented and maintained for continuation requests per medical records
    inv-23: MGFA class — required clinical class at initiation
    Required MGFA class at initiationMGFA Clinical Classification II, III, or IV
    PurposeUsed to establish disease severity for initiation of FcRn blocker therapy

    Provider Requirements and Prior Authorization

    Prior Authorization

    Imaavy prior authorization requirements

    Prior authorization is required for initial Imaavy (nipocalimab) therapy. Submit complete medical records (chart notes, laboratory values, antibody test results, MG-ADL score, MGFA classification, prior therapy history) to support the request. Initial approvals will be for up to 12 months.

    • Imaavy requests must include documentation of diagnosis of generalized myasthenia gravis (gMG).
    • Provide positive serologic testing for anti-AChR or anti-MuSK antibodies when applicable.
    • Include MGFA clinical classification and baseline MG-ADL total score.
    Denial Risk

    Requests missing required documentation (diagnosis, antibody testing, MGFA class, MG-ADL)

    Requests lacking required diagnostic documentation risk denial. Ensure submission includes chart notes confirming diagnosis, antibody testing results, MGFA class, baseline MG-ADL score, and prior treatment history.

    Clinical Background and Mechanism

    Generalized myasthenia gravis (gMG) is an antibody-mediated neuromuscular disorder in which pathogenic IgG autoantibodies impair neuromuscular transmission. FcRn blockers (agents such as efgartigimod, nipocalimab, rozanolixizumab) bind the neonatal Fc receptor (FcRn) and reduce circulating IgG levels, thereby lowering pathogenic autoantibody concentrations. This mechanism underpins the clinical rationale for using FcRn blockers in antibody-positive gMG and informs policy requirements linking treatment eligibility to antibody status, baseline severity (e.g., MG-ADL ≥ 5, MGFA class II–IV), and prior therapy failure pathways.

    Definitions and Clinical Scales

    inv-46: MG-ADL — scale definition and policy thresholds (baseline ≥5; ≥2 point improvement for continuation)
    Scale descriptionMG-ADL assesses 8 signs/symptoms; each item 0–3; total range 0–24 (higher = greater impairment)
    Initiation thresholdBaseline MG-ADL total score ≥ 5 required for initiation of FcRn blocker therapy
    Continuation criterionContinuation requires documented ≥2 point improvement in MG-ADL from baseline
    Responder definition (trial)MG-ADL responder = ≥2 point reduction sustained ≥4 consecutive weeks
    inv-47: MGFA Clinical Classification — required classes II–IV at initiation
    Required classes for initiationMGFA Clinical Classification II, III, or IV

    Policy Revision History

    2026-04-01title_and_product_updateLatest

    Policy retitled and updated to add Imaavy (nipocalimab-aahu) for intravenous (IV) administration and revise the list of applicable drug products administered by a healthcare professional.

    2026-04-01concomitant_therapy_revisions

    Revised the list of drug products patients must not be receiving in combination with Rystiggo, Vyvgart, Vyvgart Hytrulo, and Imaavy to add CD19-directed cytolytic antibodies and update FcRn blocker examples (including Imaavy in FcRn blocker lists).

    2026-04-01
    Policy Summary
    Payersierra health and life
    PolicyFcRn blocker therapies for generalized myasthenia gravis
    Policy CodePolicy 2026D0111O
    Change TypeMaterial revisions to drug list, concomitant therapy exclusions, and Vyvgart criteria
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical records showing diagnosis, antibody status, MGFA class II–IV, baseline MG-ADL ≥ 5, and required prior therapy failures.
    SourceLink
    On This Page
    Coverage Criteria for FcRn BlockersBilling and Diagnosis CodesProvider Requirements and Prior AuthorizationClinical Background and MechanismDefinitions and Clinical ScalesPolicy Revision History
    If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over the course of at least 12 months.
    see text
    >=2 point MG-ADL improvement
    Concomitant therapy and dosing: Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin; Vyvgart Hytrulo is dosed per US FDA labeling for CIDP; prescribed by or in consultation with a neurologist; initial authorization for no more than 12 months.

    Referenced drug classes/examples provided in policy.

    DocumentationMGFA class must be recorded in submitted medical records for prior authorization
    inv-24: MG-ADL responder definition — ≥2 point reduction sustained ≥4 weeks (trial-based responder definition)
    MG-ADL responder definition (trial-based)≥2 point reduction in total MG-ADL score from baseline sustained for ≥4 consecutive weeks
    ContextDefinition used in efgartigimod clinical trials to define responders
    TimingFirst reduction must occur no later than 1 week after last infusion of the cycle (trial context)
    inv-25: QMG responder definition — ≥3 point reduction sustained ≥4 weeks
    QMG responder definition (trial-based)≥3 point reduction in total QMG score from baseline sustained for ≥4 consecutive weeks
    Scale rangeQMG total score range 0–39 (higher = worse)
    Trial timingFirst reduction must occur no later than 1 week after last infusion of the cycle (trial context)
    inv-26: MG-ADL threshold — restated threshold value for quick reference
    MG-ADL quick reference thresholdMG-ADL total score ≥ 5
    UseRequired at initiation of therapy for FcRn blockers per policy
    DocumentationRecord baseline MG-ADL score in medical records submitted for prior authorization
    • Missing antibody testing, MG-ADL, or MGFA classification may result in denial.
    • Document that the patient has not failed prior course of the same agent when applicable.
    Denial Risk

    Use of listed FcRn blockers and other agents in combination prohibited

    Imaavy must not be given in combination with other listed FcRn blockers or certain other immunotherapies. Concurrent use with these agents is prohibited and may result in denial.

    • Do not combine Imaavy with other FcRn blockers (examples: Rystiggo/rozanolixizumab, Vyvgart/efgartigimod alfa-fcab, Vyvgart Hytrulo).
    • Concurrent administration with CD19-directed cytolytic antibodies, complement inhibitors, or immune globulin is also prohibited.
    Denial Risk

    Concurrent therapy exclusion

    Concurrent therapy exclusion: Imaavy must not be used concurrently with CD19-directed cytolytic antibodies, complement inhibitors, other FcRn blockers, or immune globulin. Requests indicating concurrent use will be operationally denied.

    • Examples of excluded agents: Uplizna (inebilizumab), eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan), Hizentra, Privigen, Gammagard.
    Documentation Required

    Submit medical records (chart notes, laboratory values, MG-ADL, MGFA, prior therapy history)

    Submit full medical records to support initial and continuation requests. Include chart notes, laboratory tests, documented antibody results, MG-ADL scores (baseline and on-therapy), MGFA classification, and detailed prior therapy history including durations and outcomes.

    • Initial requests: diagnosis confirmation, antibody positivity, MGFA class, baseline MG-ADL, prior immunosuppressant trial history (agents, durations, outcomes).
    • Continuation requests: on-treatment MG-ADL demonstrating ≥2 point improvement or maintenance from baseline, documentation of symptom reduction, and evidence of maintenance/reduction/discontinuation of baseline immunosuppressive therapy.
    Documentation Required

    For continuation, submit records demonstrating ≥2 point MG-ADL improvement (or maintenance) and IST changes

    For continuation of Imaavy, submit records demonstrating clinical improvement or maintenance. Required evidence includes objective MG-ADL change, reduction in signs/symptoms, and immunosuppressant dosing changes consistent with response.

    • Continuation approval requires demonstration of at least a 2-point improvement (reduction) in MG-ADL from pre-treatment baseline, or maintenance of prior benefit.
    • Also submit notes showing reduction in MG signs/symptoms and maintenance/reduction/discontinuation of baseline IST. Addition or escalation of IST or need for rescue therapy while on Imaavy is considered treatment failure.
    RoleUsed to confirm disease severity at therapy start for FcRn blockers
    Authorization evidenceMGFA class must be included in submitted medical records for prior authorization review
    inv-48: FcRn blocker / mechanism — brief definition of agent class
    DefinitionFcRn blockers are agents that bind the neonatal Fc receptor (FcRn) to reduce circulating IgG and pathogenic autoantibody levels
    ExamplesIncludes efgartigimod alfa(-fcab), nipocalimab, rozanolixizumab (listed in policy)
    Mechanism effectReduction in total IgG and disease-specific autoantibody levels demonstrated in trials
    inv-49: MG-ADL responder — trial-based responder definition used for continuation decisions
    Policy continuation responder ruleContinuation decisions use the trial-based MG-ADL responder definition: ≥2 point reduction sustained ≥4 weeks
    Documentation requiredMedical records must show sustained MG-ADL improvement and reduction in signs/symptoms for continuation
    Trial originDefinition derived from efgartigimod trials where responder status determined during treatment cycles
    inv-50: Typical CIDP — diagnostic definition entry for CIDP pathway
    Typical CIDP clinical definitionProgressive or relapsing, symmetric, proximal and distal muscle weakness with sensory involvement of at least two limbs developing over at least 8 weeks with absent or reduced tendon reflexes in all limbs
    Diagnostic criteria sourceBased on 2021 EAN/PNS revised guidelines as referenced in policy
    Electrodiagnostic supportElectrodiagnostic parameters supportive of demyelination are listed in policy (motor distal latency, conduction velocity reduction, F-wave changes, conduction block, temporal dispersion, CMAP duration)
    inv-51: CIDP variants — list of CIDP variants referenced in policy
    Listed CIDP variantsDistal, multifocal, focal, motor-only, sensory-only (policy references EAN/PNS 2021 definitions)
    ContextVariants defined by the task force as falling under CIDP diagnostic framework with variant-specific clinical patterns
    Use in policyVariants are referenced to guide diagnostic classification and eligibility for CIDP pathway therapies
    removal_of_interval_requirement

    Removed the coverage criterion that required a minimum 50-day interval between Vyvgart or Vyvgart Hytrulo treatment cycles.